申请人:Lee Sam SK
公开号:US20120183496A1
公开(公告)日:2012-07-19
The present invention provides, among other things, compounds represented by the general Formula I:
and pharmaceutically acceptable salts thereof, wherein X, Y, R
1A
, R
1B
, R
2
, and R
3
are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.